Fast Five Quiz: Alzheimer's Disease Management

Jasvinder P. Chawla, MD, MBA; Shaheen E. Lakhan, MD, PhD, MS, MEd

Disclosures

December 21, 2022

In the United States and Europe, the current focus of research and development of drugs to treat moderate to severe Alzheimer's disease has transitioned to prevention, early detection, and treatment of early-stage disease. The recent discovery of biomarkers associated with Alzheimer's disease, past evidence of protective factors against Alzheimer disease, and the failure of medication trials in patients with moderate to severe Alzheimer's disease prompted a shift toward prevention.

Vaccine trials against Alzheimer's disease are promising and could change its projections and future costs to healthcare industries worldwide, as well as lead to healthier elderly populations.

Development of medications solely for severe disease, investment in daycare programs for patients with advanced disease, and early retirement programs to prevent are not the current focus of drug research and development in the United States and Europe.

Learn more about early detection, prevention, and treatment of Alzheimer disease.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....